CLI: Definition, Uses, and Clinical Overview

CLI Introduction (What it is)

CLI most commonly refers to critical limb ischemia, a severe form of peripheral artery disease (PAD).
It describes chronic, markedly reduced blood flow to a leg or foot that can cause rest pain, non-healing wounds, or tissue loss.
CLI is a clinical term used in vascular medicine, cardiology, interventional cardiology, and vascular surgery.
Many clinicians now also use the updated term chronic limb-threatening ischemia (CLTI) to describe the same high-risk spectrum.

Why CLI used (Purpose / benefits)

CLI is used to identify a high-risk stage of PAD where blood flow is low enough to threaten the viability of the limb. In simple terms, it helps clinicians recognize when reduced circulation is no longer just a walking-limitation problem (claudication), but a situation where skin, nerves, and soft tissue may not be getting enough oxygen even at rest.

Key purposes include:

• Risk stratification: CLI signals higher risk of limb complications (such as non-healing ulcers) and often coexists with higher overall cardiovascular risk because PAD reflects widespread atherosclerosis.
• Symptom and wound interpretation: It provides a framework for interpreting rest pain, ulcers, or gangrene as potentially ischemic (blood-flow related), rather than only infectious, neuropathic, or traumatic.
• Guiding urgency and workup: CLI typically triggers more urgent vascular assessment, including objective blood-flow testing and imaging to map arterial disease.
• Directing treatment goals: In many cases, the clinical goal shifts toward limb preservation and wound healing, often requiring coordinated care (vascular evaluation, wound care, diabetes care, podiatry, and rehabilitation).

CLI is not a single test result. It is a clinical syndrome supported by symptoms, exam findings, and objective measures of impaired limb perfusion.

Clinical context (When cardiologists or cardiovascular clinicians use it)

CLI is commonly considered or discussed in scenarios such as:

• Foot or toe ulcers that do not heal as expected, especially in people with diabetes or known PAD
• Rest pain in the forefoot or toes (often worse at night) that may improve when the leg is placed in a dependent position (hanging down)
• Gangrene (dead tissue) of toes or parts of the foot
• Markedly diminished pulses in the feet, cool extremities, or other exam findings suggesting poor arterial flow
• Abnormal noninvasive perfusion tests, such as ankle-brachial index (ABI), toe pressures, or transcutaneous oxygen measurements (tests vary by clinician and case)
• Pre-procedure planning for endovascular or surgical revascularization (opening blocked arteries)
• Multidisciplinary limb-salvage discussions, particularly in patients with diabetes, kidney disease, or complex wounds
• Differentiating chronic disease from acute limb ischemia, which is a sudden arterial blockage and a different emergency condition

Contraindications / when it’s NOT ideal

Because CLI is a diagnostic label/syndrome rather than a single procedure, “contraindications” mainly mean situations where the term is not the best fit or where other diagnoses should be prioritized.

CLI may be not ideal to apply when:

• Acute limb ischemia is suspected (sudden onset of severe pain, pallor, coldness, numbness, or loss of function). Acute limb ischemia is a different entity and typically requires immediate emergency evaluation.
• A wound is more consistent with a non-arterial cause, such as:
• Venous stasis ulcers (often around the ankle with chronic swelling and skin changes)
• Pressure injuries (from prolonged pressure)
• Neuropathic ulcers (common in diabetes, often on pressure points; can coexist with ischemia)
• Pain is more consistent with non-ischemic causes, such as neuropathy, spinal stenosis, arthritis, or musculoskeletal injury (these can also coexist with PAD).
• The limb findings are driven by non-atherosclerotic vascular disease, where terminology and treatment pathways may differ (examples include vasculitis, embolic disease, thromboangiitis obliterans, or certain arterial entrapment syndromes). Evaluation varies by clinician and case.
• The term “CLI” is used without objective perfusion assessment. Many experts prefer pairing symptoms/wounds with objective measures of blood flow to reduce misclassification.

In practice, clinicians often use a broader, updated framework (commonly CLTI) that emphasizes limb threat severity and objective ischemia testing.

How it works (Mechanism / physiology)

CLI results from insufficient arterial blood flow to meet the metabolic needs of the tissues in the lower limb—particularly the foot. The most common underlying mechanism is atherosclerosis, the buildup of plaque inside arteries.

High-level physiology:

• Arterial narrowing or blockage reduces perfusion pressure and blood delivery beyond the obstruction.
• When flow is reduced enough, tissues can become ischemic even at rest, not only during walking.
• Poor perfusion impairs:
• Skin integrity and wound healing
• Resistance to infection
• Microcirculatory function (small-vessel blood flow), which can be especially relevant in diabetes and chronic kidney disease
• Ischemia can present as:
• Ischemic rest pain (often forefoot/toe pain, classically worse at night)
• Ulceration that does not heal because oxygen delivery is inadequate
• Tissue loss (gangrene) when prolonged ischemia causes cell death

Relevant anatomy (simplified):

• Blood reaches the legs through the aorta → iliac arteries → femoral arteries → popliteal artery → tibial/peroneal arteries → pedal arteries.
• CLI often involves multilevel disease, commonly including the smaller arteries below the knee in people with diabetes (distribution varies by patient).

Time course and interpretation:

• CLI is generally chronic and develops over time, but symptoms may worsen abruptly if a narrowing becomes critically tight, a clot forms on top of plaque, or infection increases tissue oxygen demand.
• Reversibility depends on the cause and severity. Some components (like pain from ischemia) may improve if perfusion improves; tissue loss may require prolonged wound care and may not fully reverse.

CLI Procedure overview (How it’s applied)

CLI is not itself a procedure. Clinically, it is assessed and managed through a structured evaluation and treatment pathway. A typical high-level workflow may look like this (exact steps vary by clinician and case):

1. Evaluation / exam – Symptom review (rest pain, walking limits), wound history, and infection screening – Vascular exam (pulses, skin temperature/color, capillary refill) and basic neurologic assessment – Review of cardiovascular risk factors (diabetes, smoking exposure, kidney disease, cholesterol disorders, hypertension) and existing heart or cerebrovascular disease

2. Preparation (risk and limb assessment) – Objective perfusion testing, commonly with ABI and/or toe pressures; additional tests may be used when ABI is less reliable (for example, calcified arteries can falsely elevate ABI) – Wound assessment (size, depth, drainage) and evaluation for infection; clinicians may involve wound care or podiatry

3. Intervention / testing (mapping the arteries) – Noninvasive imaging such as duplex ultrasound and/or cross-sectional imaging (CTA or MRA) when appropriate – Catheter angiography in selected cases, particularly when endovascular treatment is being considered

4. Immediate checks (goal alignment and limb safety) – Determine whether the plan is medical therapy alone, revascularization (endovascular or surgery), wound procedures, or a combination – Assess pain control needs and infection management as part of a coordinated plan (details vary)

5. Follow-up – Repeat clinical checks of symptoms, pulses/perfusion tests when indicated, and wound healing progress – Ongoing cardiovascular risk management and functional rehabilitation planning

Types / variations

CLI is commonly described along several clinically useful dimensions:

• Symptom-based categories
• Ischemic rest pain without tissue loss

• Tissue loss, including non-healing ulcers or gangrene

• Severity staging systems

• Rutherford classification and other staging approaches may be used to categorize symptoms and tissue loss.

• Some contemporary frameworks emphasize wound severity, ischemia level, and infection together (exact system use varies).

• Time course

• Chronic limb ischemia progressing over weeks to months (typical CLI pattern)

• Acute on chronic ischemia, where a chronic narrowing suddenly worsens (e.g., thrombosis on plaque), producing rapid symptom escalation

• Anatomic patterns

• Aorto-iliac disease (higher up in the pelvis)
• Femoro-popliteal disease (thigh/knee region)

• Infrapopliteal disease (below-knee tibial arteries), commonly relevant in diabetes

• Patient/context variations

• CLI with diabetes (often neuropathy, higher ulcer risk, and calcified arteries affecting test interpretation)
• CLI with chronic kidney disease (often more diffuse arterial disease; management complexity varies)
• CLI in the setting of prior revascularization (restenosis or graft issues may be considered)

Pros and cons

Pros:

• Helps identify a high-risk PAD stage where limb viability may be threatened.
• Encourages objective perfusion testing rather than relying on symptoms alone.
• Promotes multidisciplinary care, integrating vascular assessment, wound care, and risk-factor management.
• Provides a common clinical language for triage and urgency decisions.
• Supports structured decision-making about revascularization vs. conservative approaches (varies by clinician and case).

Cons:

• The term can be imprecise if used without objective measures of ischemia.
• CLI is a heterogeneous syndrome—two patients with “CLI” may have very different anatomy, wound burden, and prognosis.
• It may overlap with other causes of pain and ulcers (neuropathy, venous disease, infection), complicating diagnosis.
• Some clinicians consider CLI an older term and prefer CLTI-based staging to better reflect wound and infection severity.
• Focus on the limb can overshadow that PAD reflects systemic atherosclerosis, requiring broader cardiovascular risk assessment (without implying specific treatment steps).

Aftercare & longevity

Outcomes after a CLI diagnosis depend on multiple factors, and “longevity” can refer to both limb outcomes (healing, recurrence) and vascular durability after any intervention.

General factors that influence outcomes include:

• Severity at presentation: Rest pain alone differs from extensive tissue loss or infection.
• Anatomic complexity: Multilevel or small-vessel disease can be more challenging to treat; durability varies by approach and patient factors.
• Comorbidities: Diabetes, chronic kidney disease, heart disease, and frailty can affect wound healing and procedural risk.
• Tobacco exposure: Smoking is strongly associated with PAD progression; the impact of cessation varies by individual.
• Foot care and wound care quality: Offloading, dressing strategies, and infection control influence healing (specific plans vary by clinician and case).
• Follow-up and surveillance: Clinicians may monitor symptoms, pulses, noninvasive tests, and wound status to detect recurrence or complications early.
• Revascularization approach and materials: Patency and durability can vary by technique, lesion length, vessel size, and device/material choice (varies by material and manufacturer).

Many patients require ongoing vascular and wound follow-up because PAD is typically chronic and may progress.

Alternatives / comparisons

Because CLI describes severe PAD, “alternatives” usually refer to different management strategies or different ways to evaluate perfusion, depending on limb threat and patient context.

Common comparisons include:

• CLI vs intermittent claudication
• Claudication is exertional leg pain due to PAD that improves with rest and is not immediately limb-threatening.

• CLI involves rest pain and/or tissue loss and generally signals higher urgency for perfusion assessment.

• CLI/CLTI vs acute limb ischemia

• CLI is typically chronic and progressive.

• Acute limb ischemia is sudden and time-sensitive, often requiring emergency evaluation; management pathways differ.

• Medical management vs revascularization

• Medical therapy and risk-factor management are foundational in PAD, but CLI often prompts evaluation for restoring blood flow when feasible.

• The choice depends on anatomy, wound severity, comorbidities, and patient goals (varies by clinician and case).

• Endovascular vs surgical approaches

• Endovascular options (balloon angioplasty, stenting, atherectomy in selected cases) are less invasive but durability varies.

• Surgical bypass can be effective for certain patterns of disease but is more invasive and depends on conduit availability and surgical risk.

• Noninvasive testing vs invasive angiography

• ABI, toe pressures, duplex ultrasound, CTA, and MRA can provide valuable information without catheter insertion.

• Catheter angiography offers detailed mapping and can allow treatment in the same setting, but it is invasive and carries procedural risks.

• Limb salvage vs primary amputation

• Limb-salvage pathways may include revascularization plus wound care.
• In selected situations (extensive non-salvageable tissue loss, severe infection, or high procedural risk), amputation may be discussed; decisions are individualized.

CLI Common questions (FAQ)

Q: Is CLI the same thing as PAD?
CLI is usually considered a severe stage of PAD, not a separate disease. PAD can exist with mild or moderate symptoms, while CLI generally involves rest pain and/or tissue loss due to markedly reduced blood flow. Some clinicians use CLTI as a more descriptive modern term.

Q: What symptoms make clinicians think about CLI?
Common triggers include pain in the foot or toes at rest, non-healing ulcers, or gangrene. Symptoms are interpreted together with physical exam findings and objective blood-flow testing.

Q: Does CLI always cause pain?
Not always. Some people—especially those with diabetic neuropathy—may have reduced sensation and may not feel typical ischemic pain even with significant tissue injury. That is one reason ulcers and skin changes are evaluated carefully.

Q: Is CLI an emergency?
CLI is serious and time-sensitive, but it is typically chronic rather than sudden. A different condition, acute limb ischemia, is a true emergency with abrupt symptom onset. Clinicians sort these out based on timing, exam, and perfusion testing.

Q: What tests are commonly used to evaluate CLI?
Clinicians often start with noninvasive assessments like ABI and/or toe pressures, plus vascular ultrasound. CTA, MRA, or catheter angiography may be used to define arterial anatomy and plan treatment, depending on the situation.

Q: Will I need to be hospitalized?
Hospitalization depends on factors such as infection, wound severity, pain control needs, and whether an urgent procedure is planned. Some evaluations and treatments occur outpatient, while others require inpatient care. This varies by clinician and case.

Q: Is revascularization always possible in CLI?
Not always. Feasibility depends on arterial anatomy, the extent of small-vessel disease, prior procedures, and overall health status. When revascularization options are limited, clinicians may focus on wound care, infection control, and other supportive strategies.

Q: How long do results last after treatment for CLI?
Durability varies based on the type of procedure, location and length of arterial disease, and patient-specific factors. Some patients need repeat interventions over time, while others have longer-lasting results. Follow-up plans are individualized.

Q: Is CLI treatment “safe”?
Every approach—medical therapy, endovascular procedures, surgery, and wound interventions—has potential benefits and risks. Risk depends on comorbidities (such as kidney disease or heart disease), anatomy, and procedural complexity. A clinician typically discusses risk in patient-specific terms.

Q: What about cost for CLI care?
Costs vary widely based on testing (imaging type), procedures, hospitalization, wound supplies, and follow-up needs. Insurance coverage, region, and facility type also affect out-of-pocket costs. It’s common to request an estimate through the treating health system.